When does a biotech company need D&O insurance?

A biotech operator typically needs Directors and Officers (D&O) insurance from the first outside-investor financing round onward. Seed and Series A investors typically require D&O as a closing condition for the financing - the operator's legal counsel and the investor's legal counsel will both expect a program to be in place by closing date.

The floor program for a pre-clinical or Phase 1 biotech is typically $2M-$5M primary D&O with explicit Side A coverage. Side A is the most important architectural element at clinical-stage: it funds individual indemnification for board members in the event entity indemnification fails (which is common in distress scenarios). Side B and C scale with the company's financial position and exposure.

For operators at IPO-readiness, the D&O program needs material expansion - $10M-$25M primary, transactional D&O placement at $25M-$50M for the offering itself, plus public offering of securities insurance (POSI). The IPO underwriter representation is typically the forcing function for the program upgrade.